The patients with type 2 diabetes and cardiovascular disease
Conditions
Interventions
Oral administration of 2.5mg luseogliflozin once a day for 24 weeks
Sponsors
Saiseikai Fukuoka General Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Provide written informed concent 2. Aged >=30, <75 at consent 3. Type 2 diabetes mellitus 4. Grycated hemoglobin (HbA1c) (NGSP) of >= 6.5%, < 10.0% 5. previous history of any cardiovascular diseases 6. No experience of SGLT2 inhibitors
Exclusion criteria
Exclusion criteria: already taking an SGLT2 inhibitor, age < 30 years or >= 75 years, diagnosis of type 1 diabetes or insulin-dependent diabetes, symptomatic heart failure (NYHA II-IV), severe renal dysfunction (eGFR < 45 mL/min/1.73 m2), severe liver dysfunction (over 3* upper limit of normal), diabetic ketoacidosis or diabetic coma the presence of malignancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change in the septal E/e' ratio as a parameter of LV diastolic function between before and after the start of the luseogliflozin treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| The change in various parameters in echocardiogram between before and after the start of the luseogliflozin treatment | — |
Countries
Japan
Contacts
Public ContactYujiro Ina
Saiseikai Fukuoka General Hospital Department of Diabetes
Outcome results
None listed